case_images: PMC10419265_01
case_images: "Bright" appearing perivascular tissue in the echocardiography around CAA. *LAD, left coronary artery; **PA, pulmonary artery; ***AO, aorta; arrow; "bright" appearing perivascular tissue.
case_images: fped-11-1210940-g001.jpg
case_images: PMC10419265_01_fped-11-1210940-g001.jpg
case_images: F1
case_images: Despite a rapid normalization of inflammatory parameters, a third infusion of infliximab (5 mg/kg/day) was administered 1 week later due to the development of giant coronary artery dimensions (LAD: 4.9 mm, Z-score: 11.1; RCA: 5.8 mm, Z-score: 15.5) and persistent perivascular brightness (Figure 1).
case_images: Time course of clinical Kawasaki disease (KD) signs and laboratory values in relation to the prescribed KD medications (ASA, prednisone, IVIG, infliximab) and days after disease onset. LMWH, low-molecular-weight heparin; ASA, acetylsalicylic acid; IVIG, immunoglobulin; CrP, C-reactive protein.
case_images: fped-11-1210940-g002.jpg
case_images: PMC10419265_01_fped-11-1210940-g002.jpg
case_images: F2